Clinical course of COPD patients with exercise-induced elevation of pulmonary artery pressure or less severe pulmonary hypertension presenting with respiratory symptoms and the impact of bosentan intervention-prospective, single-center, randomized, parallel-group study.

Compared with baseline (Table 1 ), there was a significant decrease in mPAP at months 6 and 18 (mean difference; -2.72 at month 6; P = 0.022, -2.56 at month 18; P = 0.030), and a decreasing trend at month 12 although no significant difference was noted (mean difference; -3.18; P = 0.063; R = 0.58).

also in 47,180 other papers